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The IL-1R/TLR family has been receiving considerable attention as potential regulators of inﬂammation through their ability
to act as either activators or suppressors of inﬂammation. Asthma is a chronic inﬂammatory disease characterized by airway
hyperresponsiveness, allergic inﬂammation, elevated serum total, allergen-speciﬁc IgE levels, and increased Th2 cytokine
production.The discovery that the IL-1RI–IL-1and ST2–IL-33pathways are crucial for allergic inﬂammation has raised interest in
these receptors as potential targets for developing new therapeutic strategies for bronchial asthma. This paper discusses the current
use of neutralizing mAb or soluble receptor constructs to deplete cytokines, the use of neutralizing mAb or recombinant receptor
antagonists to block cytokine receptors, and gene therapy from experimental studies in asthma. Targeting IL-1RI–IL-1 as well as
ST2–IL-33 pathways may promise a disease-modifying approach in the future.
1.Introduction
Asthma is characterized by allergic inﬂammation of the
airways with local inﬁltration of eosinophils, mast cells, and
activated T helper lymphocytes [1]. The initial immune
response responsible for this is the generation of allergen-
speciﬁc CD4+ T helper-2 cells (Th2) that produce Th2
cytokines (IL-4, IL-5, IL-9, and IL-13), but not T helper-
1 (Th1) cytokines (IL-2, IL-12, and interferon-γ [IFN-γ]).
Overwhelming evidence in literature supports the concept
that allergicinﬂammation is driven by an imbalance between
Th1 and Th2 cytokines, favoring the Th2 immune response
[1]. IL-4, together with IL-13, is required for Th2-cell
development and is intimately involved in the regulation of
immunoglobulin E (IgE) production by sensitized allergen-
speciﬁc B cells, which is a fundamental mechanism in the
pathogenesis of allergic asthma [2]. IL-5 is the principal
cytokine involved in eosinophil growth, maturation, diﬀer-
entiation, survival, and activation [3, 4]. Cross-linking of
allergen-speciﬁc IgE on mast cells and the activation of T
cells and eosinophils during subsequent encounters with
antigens stimulates the release of various preformed and
newlysynthesized products, including histamines, cytokines,
and chemokines. Together, these lead to characteristic air-
way changes that contribute to airway obstruction, airway
hyperresponsiveness (AHR), goblet cell metaplasia, mucus
overproduction, mucosal edema, and airway remodeling [5].
Pulmonary allergic inﬂammation can be induced in
small rodents, such as BALB/c mice, is widely used as an
experimental model for human asthma, and is central to the
preclinical development of drug therapies [6]. One of the
most common murine models of allergen-induced airway
inﬂammation involves mouse sensitization using a small
dose of a protein allergen followed by allergen challenge of
the airways to induce pulmonary inﬂammation [7]. This
is usually done by injecting the protein intraperitoneally
along with an aluminum hydroxide as adjuvant to enhance
the protein’s immunogenicity [8]. After the immune system
has had a chance to mount a reaction against the antigenic
protein (sensitization) over several days, the animal receives
further antigen exposure either directly to the lungs in the
form of an aerosol or via postnasal drip following nasal
instillation (challenge). This characteristically leads to AHR,
lung eosinophilia, mucus hypersecretion, and increased IgE2 Mediators of Inﬂammation
levels, which are all features commonly associated with
human allergic asthma [5].
The IL-1 family has been involved in inﬂammatory and
immunologic responses [9]. Members contain activators and
suppressorsofinﬂammation[9].Interleukin-1receptors(IL-
1Rs) and Toll-like receptors (TLRs) are members of a large
superfamily of phylogenetically conserved proteins involved
in innate immunity and inﬂammation [10]. The common
characteristics of these two receptor families include their
presence in the cytoplasmic region of a conserved sequence
called Toll/IL-1R (TIR) domain [9, 11]. The IL-1R/TLR-
driven immune response also has an essential role in the
induction and/or regulation of allergic inﬂammation and
disease exacerbations.
ST2, one member of the IL1 receptor family, was ﬁrstly
identiﬁed as an orphan receptor in 1989 [12]. In 2005, the
discoveryofinterleukin-33(IL-33)asanST2ligandprovided
new insights into ST2 signalling pathway [13]. ST2/IL-33
signalling is involved in T-cell mediated immune responses,
particularly Th2 cells and the production of Th2-associated
cytokines [14].
Allergicasthmaisusedasanexampleofachronicinﬂam-
matory disease to show how IL-1R/TLR-related pathway
oﬀer possibilities of therapeutic intervention. Due to similar
roles in the pathogenesis of allergic inﬂammation, focus was
on the IL-1RI-IL-1 and ST2-IL-33 pathways to review their
potential as therapeutic targets for treating asthma [15].
Special attention was given to the experimental approach in
validating the possibility of targeting IL-1R/TLR to explore
emerging treatments.
2.IL-1RI-IL-1
IL-1R was ﬁrst described and cloned in the family [11, 16–
21]. The IL-1R type 1 (IL-1RI) contains three extracellular
immunoglobulin (Ig) domains [9, 11]. A second chain,
the IL-1 receptor accessory protein (IL-1RAcP) [22]h a s
been reported. It is essential for the signal transduction
for IL-1 and IL-33 and is highly homologous to IL-1RI.
IL-1RAcP forms a heterodimer with either the IL-1RI or
the IL-33Rα chain (ST2) [9]. IL-1RI and IL-1RAcP form
the receptor complex for IL-1 (both IL-1a and IL-1b) and
binds naturally occurring IL-1 receptor antagonists (IL-1Ra)
[23]. The Drosophila protein Toll has a cytosolic domain
homologous in sequence to IL-1RI [24], which is called the
TIR domain. It is also found in the cytoplasmic domains
of each TLR, sometimes shortened to the Toll-IL-1 receptor
domain [25]. The TIR domains of IL-1RI and the coreceptor
IL-1RAcP are necessary for signal transduction.
2.1. SignalingPathway. Detailed structuresforIL-1bound to
the IL-1RI/IL-1RAcP complex have been discovered, as well
as structures for IL-1RA bound to IL-1RI/IL-1RAcP [26, 27].
In crystallization studies, IL-1RI undergoes conformational
change when binding IL-1β and allows IL-1RAcP to form
the heterodimer [9]. The formation of an IL-1 receptor het-
erodimer complex results in the approximation of adjacent
TIR domains. This complex recruits intracellular adapter
molecules, including MyD88 (myeloid diﬀerentiation factor
88), IRAK (IL-1R associated kinase), and TRAF6 (tumor
necrosis factor [TNF] receptor-associated factor 6], to acti-
vate signal transduction pathways such as nuclear factor-κB
(NF-κB), AP-1 (activator protein-1), JNK (c-Jun N-terminal
kinase), and p38 MAPK (mitogen-associated protein kinase)
[21, 28].
In an animal model of asthma, persistent NF-κBa c t i v a -
tion in the bronchi is driven by granulocytes via IL-1β and
TNF-α, which both induce IκB-β degradation, perpetuating
the immune response in asthmatic airways [29, 30]. IL-1Ra
binds tightly to IL-1RI and blocks the activity of either IL-1α
or IL-1β. One of the binding sites of IL-1Ra binds to IL-1RI
with high aﬃnity such that the second binding site cannot
recruit the IL-1RAcP [9].
2.2. Studies in IL-1RI/IL-1 Pathway-Deﬁcient Mice. The
critical role of IL-1/IL-1R1 in the development of allergic
Th2 responses in both mild and more severe asthma has
been studied [31]. The role of IL-1 in pulmonary immune
responses in models of allergic asthma has been investigated
using IL-1R1-deﬁcient [IL-1R1 (−/−)] mice. Pulmonary
eosinophilic inﬂammation, goblet cell hyperplasia, priming
of CD4+ T cells in bronchial lymph nodes and their
recruitment to the lungs, and antibody responses, including
IgG, IgE, and IgA, are strongly reduced in IL-1R1 (−/−)
compared to control BALB/c mice. In contrast, in a model
of more severe asthma, eosinophilic inﬂammation, antibody
responses, and CD4+ T cell priming in lymph nodes are
comparable between IL-1R1 (−/−) and wild-type mice.
These results suggest an important role of IL-1/IL-1R1 in
developing allergic Th2 responses, but may not be necessary
for severe allergic Th2 responses.
Another study demonstrates that IL-1 plays important
roles in the development of AHR by validating IL-1α,I L - 1 β,
and the natural inhibitor of both molecules [32]. It demon-
strates that ovalbumin (OVA)-induced AHR, OVA-speciﬁc
T cell proliferation, IL-4 and IL-5 production by T cells,
and IgG1 and IgE production by B cells, in IL-1α/β-deﬁcient
[IL-1α (−/−)/β (−/−)] mice is signiﬁcantly reduced from
levels seen in wild-type mice, whereas responses seen in IL-
1RA (−/−) mice are profoundly exacerbated or enhanced.
These observations indicate that IL-1 plays important roles
in the development of AHR and in establishing an impor-
tant balance between proinﬂammatory cytokines and their
inhibitors in allergic airway disease [33].
2.3. Experimental Application in Targeting the IL-1RI/IL-
1P a t h w a y .Using the asthma animal model, the eﬀects
of targeting the IL-1RI/IL-1 pathway are summarized in
Table 1. Reagents used include recombinant adenovirus
expressing human IL-1ra (Ad-hIL-1ra), recombinant human
interleukin-1 receptor antagonist (rhIL-1ra), and neutraliz-
ing antibodies to both IL-1β and IL-1α. Following airway
sensitization with ovalbumin, there is suppression of AHR,
inﬂammatory inﬁltration, and IL-5 production after antigen
challenge in mice expressing the IL-1Ra adenovirus [34].
Using guinea pigs sensitized with diﬀerent allergens, twoMediators of Inﬂammation 3
Table 1: Eﬀect of therapeutic experiments Targeting IL-1RI/IL-1 pathway.
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studies using rhIL-1ra also demonstrate reduced airway
symptoms induced by allergen challenge [35, 36]. Regarding
the eﬀect on inﬂammation, there is decreased expression of
adhesion molecules only in one study [36]. In mice treated
with neutralizing anti-IL-1β antibodies, AHR to inhaled
antigen is partially reduced but with a concomitant decrease
in the expression of other adhesion molecules, as well as the
suppression of IL-4 [37].
3.ST2-IL-33
IL-33, another IL-1-like cytokine, drives the production
of Th2-associated cytokines from in vitro polarized Th2
cells. In vivo, IL-33 induces the expression of IL-4, IL-
5, and IL-13 and leads to severe pathologic changes in
mucosalorgans[13].MiceinjectedwithhumanIL-33exhibit
impressivepathologicchangesinthearterialwalls,lungs,and
intestinal tissues [13]. Of particular relevance to the concept
of IL-33-driven Th2 response is the prominent eosinophilic
inﬁltration in lung tissue. Airway smooth muscle cells have
IL-33 expression in both the protein and mRNA levels. IL-
33 expression increases in bronchial biopsies in asthmatic
subjects compared to controls, as well as subjects with severe
asthma [38].
IL-33 mediates its biologic eﬀects via ST2, an IL-1
receptor-related protein speciﬁcally expressed on mast cells
and Th2 lymphocytes [15] that has been shown to function
as an important eﬀector molecule of Th2 responses in some
experimental settings, including mouse asthma models. IL-
33 administration induces AHR and goblet cell hyperplasia
through the induction of IL-4, IL-5, and IL-13 entirely inde-
pendent of the acquired immune system. Administration of
IL-33inducesAHRandgobletcellhyperplasiainthelungsin
the absence of an adaptive immune system [39]. It stimulates
mast cells into producing IL-13 in an FcεRI-independent
manner [40].
A prior study has shown ST2 to be highly expressed on
T h 2c e l l sa n di ta p p e a r st op l a yar o l ei nT h 2c e l la c t i v a t i o n
[41]. The ST2 gene is a member of the IL-1 receptor family,
producing a secreted soluble form, soluble ST2 (sST2), and
a transmembrane form, ST2L [42]. The structure of ST2L
is similar to that of IL-1 receptor type I (IL-1RI), which
consists of three extracellular immunoglobulin domains and
an intracellular Toll/IL-1 receptor domain. Although the
extracellular domain is common to sST2 and ST2L, sST2
lacks the trans-membrane and intracellular Toll-interleukin-
1r e c e p t o rd o m a i n s[ 15].
Beyond its role as a therapeutic target, sST2 has also
emerged as a disease biomarker. Previous studies in human
patients and animal models have shown that the level of
sST2 in sera is elevated in asthma [43, 44]. Therefore, it
is suggested that sST2 also plays a critical role in Th2 cell-
mediated diseases. Administering a recombinant sST2-Fc
fusion protein or a sST2 expression vector to asthmatic
mice eﬀectively attenuates inﬂammatory responses and4 Mediators of Inﬂammation
Table 2: Eﬀect of therapeutic experiments Targeting ST-2/IL-33 pathway.
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decreases Th2 cytokine production [45]. These therapeutic
experiments indicate that sST2 negatively regulates Th2 cell-
mediated immunologic responses, as opposed to ST2L.
3.1. Signaling Pathway. The ST2 receptor is similar to
the IL-1RI and IL-18Rα in that it is composed of three
extracellular Ig domains and an intracellular Toll domain.
T1/ST2-dependent IL-33 responses resemble classical IL-1-
like signaling, consistent with IL-33 receptor signaling via
the recruitment of a coreceptor, IL-1RAcP [28]. IL-33 forms
a heterodimer complex with ST2 and IL-1RAcP for signal
transduction [46, 47]. Thus, IL-1RAcP represents a shared
co-receptor within the IL-1 family that is essential for IL-
33 signaling via T1/ST2, aside from the IL-1 signaling.
Binding of IL-33 to ST2 receptor activates NF-κBa n d
MAPKs,inducesTh2cytokineexpression,andleadstosevere
pathologic changes in mucosal organs. ST2 can sequester
TLR adaptor molecules such as MyD88 [48], while TRAF6
is a critical signal transducer in the IL-33 signaling pathway
[49].
3.2. Studies in ST2/IL-33 Pathway-Deﬁcient Mice. ST2 (−/−)
micedevelopreducedallergicairwayinﬂammationcompared
to wild-type (WT) mice. This is associated with reduced
diﬀerentiation of IL-5+ T cells. However, IL-4 and IL-13
levels are similar in WT and ST2 (−/−)m i c e .T h e r ei s
a less pronounced increase in total cell, macrophage, and
eosinophil accumulation in the BAL ﬂuids of ST2 (−/−)
mice compared to WT mice [50]. These indicate that IL-
33/ST2 signaling is an important pathway in allergic airway
inﬂammation. IL-33 may be involved in lung macrophage
activation in clinical asthma and may play a signiﬁcant role
in the ampliﬁcation of alternatively activated macrophage
(AAM) polarization and chemokine production, which con-
tribute to both innate and Ag-induced airway inﬂammation
[51].
Using a primary pulmonary granuloma model induced
with Schistosoma mansoni eggs, Townsend et al. have
demonstrated that granuloma formation, characterized by
eosinophil inﬁltration, is abrogated in T1/ST2-deﬁcient mice
[52]. Naive immune cell populations, cytokine levels, Th1
and Th2 cell development, and total Ig isotype produc-
tion are normal in T1/ST2-deﬁcient mice. In the absence
of T1/ST2-expression, induction of primary synchronous
pulmonary granuloma formation and Th2 cytokine (IL-4
and IL-5) production occurs in response to the formation
ofsecondarypulmonarygranuloma.Suchdatademonstrates
clearly that T1/ST2 expression plays a role in the develop-
ment of Th2-like cytokine responses.
3.3. Experimental Application in Targeting the ST2/IL-33
Pathway. Using the asthma animal model, the eﬀects of
targeting the ST2/IL-33 pathway is summarized in Table 2.
Reagents used include neutralizing antibodies against IL-33,
neutralizing antibodies against T1/ST2, recombinant sST2,
and recombinant ST2-expressing plasmid. Treatment with
anti-IL-33 signiﬁcantly reduces serum IgE secretion, the
number of eosinophils and lymphocytes, and concentrations
of IL-4, IL-5, and IL-13 in bronchioalveolar lavage ﬂuid
compared to administering a control antibody, which indi-
cate that blocking IL-33 may be a new therapeutic strategy
for allergic asthma [53]. Blocking IL-33–T1/ST2 signaling
using an antibody against T1/ST2 abrogates persistent AHR,
suggesting that the IL-33–T1/ST2 pathway is necessary not
only in the development of an allergic response but also
for its maintenance. Anti-T1/ST2 antibody also signiﬁcantly
reduces the expression of IL-4. In contrast, IL-13 levels are
unchanged [54].
In a murine model of asthma, pretreatment with sST2
reduces IL-4, IL-5, and IL-13 production from IL-33-
stimulated splenocytes [42]. This indicates that sST2 acts as
a negative regulator of Th2 cytokine production and allergic
airway inﬂammation modulates the biological activity of
IL-33 signaling. Soluble ST2 directly binds to IL-33 and
suppresses the activation of NF-κB in EL-4 cells stably
expressingST2L,suggestingthatthecomplexofsST2andIL-
33 fails to bind to ST2L. Enhanced expression levels of sST2
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Figure 1: IL-1RI—IL-1and T1/ST2—IL-33 pathways involved in allergic inﬂammation in asthma. “+” or “−” denote enhanced/activated or
attenuated/suppressed eﬀects of modulating signaling pathways, respectively. IL-1RI, IL-1 receptor type I; IL-1RAcP, IL-1 receptor accessory
protein; IL-1Ra, IL-1 receptor antagonist; TIR, Toll/IL-1 receptor domains; sST2, soluble ST2; ST2L, trans-membrane ST2; NF-κB, nuclear
factor-κB; MAPK, mitogen-activated protein kinase; ERK, extracellular signalregulated kinase. Modiﬁed from [13, 21, 29, 30].
drastic reduction in the number of eosinophils and in IL-4
and IL-5 levels in BAL ﬂuid [44].
4. Conclusions andFuturePerspectives
Collectively, the IL-1RI−IL-1 and T1/ST2−IL-33 pathways
are critical for immunologic control of allergic inﬂammation
(Figure 1). From asthma animal studies, emerging strategies
for asthma treatment are aimed at restoring the imbalance
in cytokine (IL-1 and IL-33) and signaling pathways (IL-
1RI and ST2) that mediate inﬂammatory and structural
changes, and in skewing the cytokine proﬁle away from a
pro-inﬂammatory response towards a regulatory response.
Potential therapeutic approaches may identify new strategies
targeting key molecular mediators that drive inﬂammatory
responses in asthmatic lungs. Such strategies include the
depletion of cytokines using neutralizing mAb and solu-
ble receptor constructs, receptor blocking via binding to
recombinant receptor antagonists, small-molecule receptor
antagonists or neutralizing mAb [55], and target receptors
or cellular signal transduction pathways that are activated
following cytokine receptor ligation, and gene therapy
(expressing receptor antagonists or soluble receptor). Such
approaches provide disease-modifying treatments.
Recently, there has been much focus on the signaling
pathways involved in asthma. Among these, the MAPK
pathwaymembersJNKandp38haveattractedmuchinterest,
aside from NF-κB, AP-1, and signal transducer and activator
of transcription (STAT)-6 [56]. These signaling pathways
are all involved in the IL-1RI—IL-1 and T1/ST2—IL-33
pathways. With advances in knowledge of cellular and
molecular mediators involved in inﬂammation underlying
asthma, there is much promise the future development of
potential new therapeutics.
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